



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Anti-beta 1 integrin [AIIB2] Standard Size Ab03450-10.3

This antibody was created using our proprietary Fc Silent™ engineered Fc domain containing key point mutations that abrogate binding to Fc gamma receptors.

This chimeric human antibody was made using the variable domain sequences of the original Rat IgG1 format for improved compatibility with existing reagents assays and techniques.

Isotype and Format: Human IgG1, Fc Silent™, Kappa

Clone Number: A1B2

Alternative Name(s) of Target: integrin beta 1; Integrin beta-1-binding protein 1; Integrin cytoplasmic domain-associated protein 1 (ICAP-1)

UniProt Accession Number of Target Protein: O14713

Published Application(s): FACS, in vivo, inhibition, IP, FC

Published Species Reactivity: Human, Mouse

Immunogen: The original antibody was isolated by immunizing a Lewis rat with JAR choriocarcinoma cells.

Specificity: The antibody specifically binds β 1 integrin extracellular domain.

Application Notes: The antibody immunoprecipitated the integrin subunits (Hall et al., 1990). This antibody was used for detection of β 1 integrin expressed on CHO cells by flow cytometry (Takada et al., 1993; PMID: 7688727). The original format of the antibody or its F(ab')₂ fragments applied to single cells were capable of down-modulating β 1 integrin signaling pathways (Wang et al., 1998; PMID: 9843973 and Weaver et al., 1997; PMID: 9105051). The antibody was used in immunofluorescence characterization of integrins in the HMT-3522 cells (Weaver et al., 1997; PMID: 9105051). The antibody inhibited tumor cell growth in several breast cancer cell lines (T4-2, MDA-MB-231, BT474, SKBR3, and MCF-7) and one nonmalignant cell line (S-1). Further, β 1 integrin inhibition resulted in a significant loss of cancer cells, associated with a decrease in proliferation and increase in apoptosis, and a global change in the composition of residual colonies (Park et al., 2010; PMID: 16452209). The antibody was found to reduce the frequency of solid tumor stem cells. The antibody inhibited the growth of colon tumors and reduced the percentage of CD44+ cells. Tumors treated in mice showed a decrease when treated with the antibody. The humanized version of the antibody was constructed, showing potential for therapeutic uses (WO2009009114A3).

Antibody First Published in: Hall et al. The alpha 1/beta 1 and alpha 6/beta 1 integrin heterodimers mediate cell attachment to distinct sites on laminin. J Cell Biol (1990) 110 (6): 2175-2184. PMID:

Note on publication: The original paper describes the generation and characterization of the antibody.

Product Form

Size: 200 μ g Purified antibody.

Purification: Protein A affinity purified

Supplied In: PBS with 0.02% Proclin 300.

Storage Recommendation: Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.

Concentration: 1 mg/ml.

Important note - This product is for research use only. It is not intended for use in therapeutic or diagnostic procedures for humans or animals.